Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial
- 1 July 2008
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 165 (7), 844-854
- https://doi.org/10.1176/appi.ajp.2008.07111779
Abstract
Objective: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer’s disease and psychosis or agitated behavior. Method: The Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) Alzheimer’s disease effectiveness study included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician’s discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals. Results: In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo. Conclusion: In this descriptive analysis of outpatients with Alzheimer’s disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life.Keywords
This publication has 31 references indexed in Scilit:
- Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer DiseaseArchives of General Psychiatry, 2007
- Donepezil for the Treatment of Agitation in Alzheimer's DiseaseNew England Journal of Medicine, 2007
- National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.Current Alzheimer Research, 2007
- Effectiveness of Nonpharmacological Interventions for the Management of Neuropsychiatric Symptoms in Patients With DementiaArchives of Internal Medicine, 2006
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseNew England Journal of Medicine, 2006
- Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology, 2006
- Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled TrialsAmerican Journal of Geriatric Psychiatry, 2006
- Systematic Review of Psychological Approaches to the Management of Neuropsychiatric Symptoms of DementiaAmerican Journal of Psychiatry, 2005
- Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months: The LASER-AD StudyAmerican Journal of Geriatric Psychiatry, 2005
- Epidemiology of and Risk Factors for Psychosis of Alzheimer’s Disease: A Review of 55 Studies Published From 1990 to 2003American Journal of Psychiatry, 2005